49 results about "Guaiacol Glyceryl Ether" patented technology

The invention discloses a dextromethorphan hydrobromide and guaiacol glycerin ether oral liquid. The oral liquid contains dextromethorphan hydrobromide, guaiacol glycerin ether, acidifying and alkalizing agents and purified water, wherein the acidifying and alkalizing agents are used for regulating the pH value of the dextromethorphan hydrobromide and guaiacol glycerin ether oral liquid to be 4.0-5.5.

The invention discloses an electronic cigarette atomizing liquid, which mainly comprises: 3-5%m / v of tobacco leaf extract, 50-70%m / v of propanediol, 5-10%m / v of purified water, 3-5%m / v of tobacco essence, 0-3%m / v of nicotine, 0.2-1%m / v of stabilizer, and 3-8%m / v of thickening agent. The liquid further comprises codeine phosphate, ephedrine, guaiacol glycerol ether, chlorpheniramine, hain liquidum, syrup or the like. Because of no harm of second-hand smoke, the invention can be used at public places without influence to body health of others. The invention is capable of treating cough, hacking cough, itchy throat, abundant expectoration, sensitive cough caused by acute upper respiratory tract infection of fever, influenza or the like while enjoying smoking.

The invention provides a compound dextromethorphan hydrobromide syrup and a preparation method for the same. The compound dextromethorphan hydrobromide syrup is used for eliminating phlegm in cough, and comprises dextromethorphan hydrobromide, guaifenesin and a bacillus natto extract. The syrup improves the safety of medication and is especially suitable for children, reduces bitter taste and the consumption of a flavouring agent, improves the stability, especially the colour of solution and the stability of the colour, and improves the curative effect on the cough caused by cold and bronchitis simultaneously.

The invention discloses an improvement method of a compound glycyrrhiza oral solution production technology. The method comprises the steps of by taking 120ml of extractum glycyrrhizae liquidum, adding 120ml of glycerinum, evenly mixing, adding 500ml of water and diluting; then adding a proper amount of concentrated ammonia solution, and adjusting the pH value to be 8.00-9.00 to obtain an extractum glycyrrhizae liquidum solution; taking 5g of guaiacol glycerol ether, and adding a proper amount of hot water for dissolving to obtain guaiacol glycerol ether solution; adding the guaiacol glycerol ether solution into the extractum glycyrrhizae liquidum solution and stirring at the same time, adding 10g of sodium alginate and 5g of sodium carboxymethyl cellulose, and stirring for dissolving to obtain mixed solution; adding 180ml of compound camphor tineture into the mixed solution, evenly stirring, slowing adding right amount of concentrated ammonia solution, adjusting the pH value of the solution to be 8.00-8.50, and then adding a proper amount of water to form 1000ml of solution; evenly stirring, filtering and carrying sterilization to obtain the compound glycyrrhiza oral solution. The method solves the problems that the compound glycyrrhiza oral solution is easy to precipitate, easily goes bad, is unstable in product quality, etc.

The invention relates to a method for separating guaiacol glyceryl ether enantiomer through a simulated moving bed chromatography technology. The method comprises the steps of: coating cellulose-tris(3,5)-dimethylphenylcarbamate on silica gel as a chiral stationary phase, and n-hexane and ethanol mixture as a mobile phase by adopting a simulated moving bed chromatography system; separating the high-purity single enantiomer of R-(-)-guaiacol glyceryl ether and S-(+)-guaiacol glyceryl ether from racemic guaiacol glyceryl ether, wherein the mass fraction can achieve more than 99%. According to the method, the simulated moving bed chromatography technology is a continuous process and is simple in technique, and easy to automate, and on the basis of ensuring the purity and productivity of the products, the solvent in the whole process can be recycled, and the low-cost and pollution-free production mode can be realized.

The invention provides six liquid compositions containing phenylephrine hydrochloride. The six liquid compositions contain the following active substances: a composition 1: phenylephrine hydrochloride, brompheniramine maleate and dextromethorphan hydrobromide; a composition 2: phenylephrine hydrochloride, acetaminophen, guaiacol glyceryl ether and dextromethorphan hydrobromide; a composition 3: phenylephrine hydrochloride, chlorpheniramine maleate, acetaminophen and dextromethorphan hydrobromide; a composition 4: phenylephrine hydrochloride, acetaminophen and dextromethorphan hydrobromide; a composition 5: phenylephrine hydrochloride, acetaminophen and diphenhydramine hydrochloride; and a composition 6: phenylephrine hydrochloride, acetaminophen and guaiacol glyceryl ether. The inventor finds that the stability of the six liquid compositions is related to the pH value through research. The liquid composition can be used for treating respiratory diseases caused by cold, including virusinfection, such as influenza and cold, as well as allergy, sinusitis, rhinitis and the like.

The present invention discloses a kind of cough-relieving and phlegm-eliminating medicine composition, and is especially orally taken medicine composition dripping pill with guaiamar as active component. The guaiamar dripping pill has great medicine carrying amount, fast medicine releasing, fast acting, high bioavailability, less toxic side effect, convenient taking and low cost. The guaiamar dripping pill is prepared with guaiamar as active component, and through adding medicinal carrier as matrix, heating to obtain melt and / or emulsion and / or suspension of guaiamar and matrix, and dropping into condensating agent in dripping pill machine to form through shrinking.

The invention discloses Guaifenesin and Dextromethorphan sustained release tablets and a preparation method thereof. The Guaifenesin and Dextromethorphan sustained release tablets are composed of dextromethorphan hydrobromide and guaifenesin. The guaifenesin is a phlegm-expelling agent, and is capable of reflexively promoting increase of respiratory tract gland secretion by stimulating gastric mucosa to cause slight nausea, phlegm is diluted and coughed up; dextromethorphan hydrobromide is a central antitussive agent, has detect effect on coughing center of medulla oblongata, can inhibit cough reaction, and generates no addition. The Guaifenesin and Dextromethorphan sustained release tablets are used for treating cough and expectoration due to upper respiratory infection and bronchitis; compared with various same kinds of the product, the Guaifenesin and Dextromethorphan sustained release tablets have dual efficacies of eliminating phlegm and relieving cough, has the advantages of definite therapeutic effect, stable quality, and convenient administration, and is an ideal selection for medicine capable of relieving cough and resolving phlegm.